NEW YORK (GenomeWeb) – Quidel reported after the close of the market on Tuesday that its first quarter revenues rose 130 percent year over year, primarily driven by incremental revenues from an acquired cardiac immunoassay business and sales of influenza immunoassay products.

For the three months ended March 31, revenues rose to $169.1 million from $73.7 million in Q1 2017, and beating the average analysts' estimate of $150.9 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.